SPIA
AMLX icon

Steward Partners Investment Advisory’s Amylyx Pharmaceuticals AMLX Stock Holding History

Steward Partners Investment Advisory’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18K Hold
1,000
– – ﹤0.01% 3456
2026
Q1 		$13.9K Sell
1,000
-500
-33% -$7.03K ﹤0.01% 3408
2025
Q4 		$18.1K Hold
1,500
– – ﹤0.01% 3180
2025
Q3 		$20.4K Sell
1,500
-500
-25% -$4.71K ﹤0.01% 3086
2025
Q2 		$12.8K Hold
2,000
– – ﹤0.01% 3103
2025
Q1 		$7.08K Hold
2,000
– – ﹤0.01% 3255
2024
Q4 		$7.56K Hold
2,000
– – ﹤0.01% 3215
2024
Q3 		$6.48K Hold
2,000
– – ﹤0.01% 3109
2024
Q2 		$3.8K Hold
2,000
– – ﹤0.01% 3128
2024
Q1 		$5.68K Hold
2,000
– – ﹤0.01% 3001
2023
Q4 		$29.4K Sell
2,000
-200
-9% -$3.06K ﹤0.01% 2210
2023
Q3 		$40.3K Buy
2,200
+1,100
+100% +$23.3K ﹤0.01% 2006
2023
Q2 		$23.7K Buy
1,100
+100
+10% +$2.7K ﹤0.01% 2205
2023
Q1 		$29.3K Sell
1,000
-100
-9% -$3.47K ﹤0.01% 2087
2022
Q4 		$40.6K Buy
1,100
+50
+5% +$1.77K ﹤0.01% 1926
2022
Q3 		$30K Sell
1,050
-50
-5% -$1.25K ﹤0.01% 2016
2022
Q2 		$21K Hold
1,100
– – ﹤0.01% 2194
2022
Q1 		$14K Buy
+1,100
New +$24.8K ﹤0.01% 2513

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Steward Partners Investment Advisory's AMLX Position: Q2 2026 in Review

Steward Partners Investment Advisory held its Amylyx Pharmaceuticals (AMLX) position steady in Q2 2026 at 1,000 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #3456.

Steward Partners Investment Advisory first reported a position in AMLX in Q1 2022 and has held it in 18 quarters since. The position peaked at $40.6K in Q4 2022. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Steward Partners Investment Advisory held 1,000 shares of Amylyx Pharmaceuticals worth $18K as of Q2 2026.
  • Steward Partners Investment Advisory left its Amylyx Pharmaceuticals share count unchanged in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3456 holding.
  • Steward Partners Investment Advisory first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Steward Partners Investment Advisory's Amylyx Pharmaceuticals position peaked at $40.6K in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.